Last updated: May 23, 2026
Sotalol hydrochloride supply in the US market is dominated by a mix of: (1) injectable and oral finished-dose manufacturers selling through wholesalers and distributors; (2) API makers supplying US and global generics; and (3) contract manufacturers that package and label finished product under abbreviated new drug and private label programs. Without verified, product-specific listing data for your target strength/dosage form and labeler, a precise supplier list can’t be stated without introducing errors.
What companies supply sotalol hydrochloride API and finished dosage forms?
Answer: Supplier visibility depends on the dosage form (tablets vs injection) and strength. In practice, most procurement programs separate sotalol hydrochloride into two lanes: API sources (bulk drug substance) and finished-dose sources (NDC labelers and contract packers). Procurement teams typically validate candidates using FDA Drug Product listing and API manufacturing disclosures tied to DMFs/letters of authorization.
Which dosage forms have distinct supplier sets (tablets vs injection)?
- Oral tablets (sotalol HCl): typically sourced from multiple generic manufacturers and contract manufacturers; labelers vary by NDC.
- Injectable (sotalol hydrochloride injection): fewer manufacturers; supply tends to be more concentrated and more sensitive to manufacturing disruptions.
How do API suppliers connect to finished-dose manufacturers?
Most finished-dose generics buy sotalol hydrochloride API from one or more qualified API manufacturers, then produce under CGMP with controlled sourcing. For due diligence, buyers map:
- FDA DMF coverage (API site and process disclosure)
- Finished-dose labeler CGMP inspections
- Raw material and intermediate vendors used in the API route
- Sterility/heat-stability constraints for injectable lines
Which NDC labelers are the key US suppliers of sotalol hydrochloride tablets?
Answer: The specific US “supplier” set is the set of NDC labelers marketing sotalol hydrochloride tablets in the US, and it changes with product launches, discontinuations, and authorized generics. Determining the exact list requires NDC-level data for the target strength and dosage form.
How to structure a sourcing list for tablets
Procurement teams generally maintain a table with:
- NDC
- Strength (mg)
- Dosage form (tablet)
- Labeler/manufacturer name
- Current marketing status
- Pack size and storage conditions
- Product type (ANDA generic, authorized generic, private label)
Who supplies sotalol hydrochloride injection in the US?
Answer: Injectable sotalol hydrochloride is typically supplied by a smaller number of labelers than tablets, with higher batch-level scheduling constraints and tighter quality documentation.
What supply chain constraints matter most for injectable sotalol
- Sterile processing line capacity and validation status
- Hold times and filtration/sterilization method
- Container-closure system compatibility
- API impurity profile controls (chloride balance, related substances)
- Environmental monitoring and aseptic processing documentation
What contract manufacturing and packaging partners support sotalol products?
Answer: Many sotalol hydrochloride finished-dose programs rely on CMOs/packagers for finishing, packaging, and labeling. The CMO identity is typically not publicly consolidated in one place; it must be mapped through FDA listing/manufacturing site information, inspection records, and labeler disclosures.
How procurement identifies the real manufacturer behind an NDC
- Compare labeler name to manufacturing sites listed in FDA product registration
- Cross-check inspection history and firm names
- Map the CMOs used for packaging and labeling under the labeler’s Quality System
How do wholesalers and distributors shape “supplier” availability for sotalol?
Answer: In most US channels, branded and generic finished-dose products flow through major wholesalers (and GPO contracts) after NDC stocking decisions by distributors. Availability is impacted by:
- Distribution agreements with labelers
- Allocation during shortages
- Contract coverage under institutional formularies
- Case pack and lead time constraints
What procurement teams watch
- Allocation announcements tied to batch yield or sterility failures (injectables)
- Lead-time swings driven by API delivery variability
- Recalls and complaint rates that force alternate supply lanes
What sourcing risks exist for sotalol hydrochloride API and finished product?
Answer: Sotalol supply risk clusters around API quality consistency, single-site manufacturing dependence for injectables, and regulatory enforcement that can pause a firm’s batches.
Key risk drivers
- API impurity drift from changes in starting material or step yield
- Tight impurity specifications creating qualification barriers for alternates
- DMF changes or manufacturing site transfers that delay approvals
- Batch rejections leading to product discontinuations and NDC-level shortages
How many supplier candidates should a procurement team qualify for sotalol?
Answer: For tablets, qualification can often support multiple alternates due to broader market competition. For injectables, a dual-source strategy is more common, with deeper safety stock planning.
Practical qualification targets
- At least 2 qualified supply lanes for tablets
- At least 1-2 qualified supply lanes for injection, with additional safety stock for critical customers
- Minimum qualification package: COA trends, impurity profiles, stability, and deviation history
Key Takeaways
- “Suppliers for sotalol hydrochloride” depends on whether you mean API sources or finished-dose (NDC labelers), and it differs between tablets and injection.
- The procurement-ready supplier list must be built from NDC labeler/manufacturer data for the exact strength and dosage form, plus DMF-linked API sourcing.
- Supplier availability is shaped by wholesale stocking and batch-level manufacturing constraints, especially for injection.
- Qualification and supply-risk controls should prioritize API impurity consistency and manufacturing-site continuity.
FAQs
- How do I find the API DMF-linked suppliers for sotalol hydrochloride?
- What is the difference between the NDC labeler and the actual manufacturer for sotalol hydrochloride?
- Which quality attributes most affect acceptance of sotalol hydrochloride API for generics?
- What typically drives sotalol hydrochloride injection shortages versus tablet shortages?
- How should procurement set safety stock for sotalol hydrochloride during supply disruptions?
References
- FDA. “Drug Product Database (NDC Directory).” U.S. Food and Drug Administration.
- FDA. “Drug Master Files (DMF) and Letters of Authorization information.” U.S. Food and Drug Administration.
